Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00125957
Status:
COMPLETED
Last Update Posted:
2014-08-06
First Post:
2005-08-01
Brief Title:
The Effects of Wellbutrin Bupropion on Residual and Cognitive Symptoms in SSRI-treated Depression
Sponsor:
Mclean Hospital
Organization:
Mclean Hospital
Study Overview
Official Title:
The Effects of Wellbutrin Bupropion on Residual and Cognitive Symptoms in SSRI-treated Depression
Status:
COMPLETED
Status Verified Date:
2014-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Many people with depression are treated with a serotonin-specific reuptake inhibitor anti-depressant SSRI and feel better Although many people feel better they do not feel completely well Often individuals continue to complain of cognitive problems such as lack of attention diminished motivation and impaired problem-solving This study looks at whether residual and cognitive symptoms of depression in individuals are affected by the addition of Wellbutrin bupropion
Detailed Description:
As many as 65-75 of treated patients continue to experience residual symptoms of depression Cognitive impairments feature frontal cognitive dysfunction Many experts believe that executive functions are better predictors of functional level than psychiatric diagnoses
Frontal cognitive impairment and changes in neuroimaging are seen in individuals depleted of tryptophan a serotonin precursor These cognitive changes do not improve following serotonin-specific reuptake inhibitor treatment and at least one study has found that executive dysfunction predicts non-response to fluoxetine In many patients remission of mood symptoms in depression requires medications to target non-serotonergic neurotransmitter systems Brain areas mediating executive functions receive rich noradrenergic inputs and norepinephrine is known to be intimately involved in many of the executive functions
A better understanding of serotonergic and catecholaminergic interactions would enable evidence-based treatment of depression which maximizes executive cognitive functions This study examines the hypothesis that individuals treated with Wellbutrin will have higher scores on tests of executive functions and lower scores on depression indices
Frontal cognitive impairment and changes in neuroimaging are seen in individuals depleted of tryptophan a serotonin precursor These cognitive changes do not improve following serotonin-specific reuptake inhibitor treatment and at least one study has found that executive dysfunction predicts non-response to fluoxetine In many patients remission of mood symptoms in depression requires medications to target non-serotonergic neurotransmitter systems Brain areas mediating executive functions receive rich noradrenergic inputs and norepinephrine is known to be intimately involved in many of the executive functions
A better understanding of serotonergic and catecholaminergic interactions would enable evidence-based treatment of depression which maximizes executive cognitive functions This study examines the hypothesis that individuals treated with Wellbutrin will have higher scores on tests of executive functions and lower scores on depression indices
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None